- Home
- PARR vs EYPT Comparison
PARR vs EYPT Comparison
Compare PARR & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PARR | EYPT |
|---|---|---|
| Founded | 1984 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Integrated oil Companies | Biotechnology: Laboratory Analytical Instruments |
| Sector | Energy | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.5B |
| IPO Year | 2000 | 2005 |
Fundamental Metrics
Financial Performance| Metric | PARR | EYPT |
|---|---|---|
| Price | $53.93 | $13.25 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $48.80 | $31.80 |
| AVG Volume (30 Days) | 1.3M | ★ 1.7M |
| Earning Date | 05-26-2026 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1313.56 | N/A |
| EPS | ★ 7.16 | N/A |
| Revenue | ★ $2,443,066,000.00 | $7,539,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.98 | $965.51 |
| P/E Ratio | $7.42 | ★ N/A |
| Revenue Growth | ★ 30.99 | N/A |
| 52 Week Low | $12.04 | $3.91 |
| 52 Week High | $54.23 | $19.11 |
Technical Indicators
Market Signals| Indicator | PARR | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 73.24 | 36.41 |
| Support Level | $33.67 | $11.88 |
| Resistance Level | N/A | $14.24 |
| Average True Range (ATR) | 2.44 | 1.16 |
| MACD | 0.81 | -0.41 |
| Stochastic Oscillator | 98.58 | 4.05 |
Price Performance
Historical ComparisonAbout PARR Par Pacific Holdings Inc.
Par Pacific Holdings Inc is an oil and gas company that manages and maintains interests in energy and infrastructure businesses. The company has three reportable segments namely Refining, Under its refining business, the company produces ultra-low-sulfur diesel, gasoline, jet fuel, marine fuel, LSFO, and other associated refined products. Its Retail includes operation licenses out brands to serve the retail consumer. Through the Logistics segment, crude shipments are delivered to the refineries, in addition to finished products that are exported. It generates maximum revenue from the Refining segment.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Inc focuses on developing and commercializing innovative therapeutics for serious retinal diseases. It develops therapies for serious retinal diseases to provide durable treatments that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained release product candidate for retinal diseases with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.